Giving patients a chance is what drives us. We are committed to developing safe and effective therapies for people suffering from a wide range of fibrotic diseases.

Pliant is currently targeting fibrotic diseases in a variety of organs and conditions, including the lung (IPF), liver (primary sclerosing cholangitis and NASH), kidney (renal fibrosis), skin (systemic sclerosis), muscle (Duchenne muscular dystrophy) and the gastrointestinal tract (intestinal fibrosis in inflammatory bowel disease).